Navigation Links
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
Date:3/27/2009

CORAL GABLES, Fla., March 27 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today reported financial results for the fourth quarter and year ended December 31, 2008.

"Catalyst made significant progress in 2008," said Patrick J. McEnany, Chief Executive Officer of Catalyst Pharmaceutical Partners. "During the year, we initiated two U.S. multi-center, Phase II, double-blind, placebo-controlled trials evaluating CPP-109 as a potential treatment for cocaine and methamphetamine addiction. In September we executed a successful equity financing for $4.5 million just prior to the deterioration of the capital markets and the economy. This equity raise, combined with the recently announced change in our clinical development program, provides Catalyst with sufficient working capital through 2010. Furthermore, once we report initial top-line results for our U.S. Phase II cocaine trial, our strengthened balance sheet should allow us to engage potential corporate partners and explore a variety of transactions on terms that may prove to be more favorable to our shareholders. Concurrently, we are actively pursuing government funding from agencies that operate under the National Institutes of Health umbrella to further our development plans for large-scale clinical trials using CPP-109 to treat cocaine and methamphetamine addiction, as well as pilot studies for other addictions, such as alcohol and nicotine abuse, and obsessive-compulsive disorders, including binge eating."

Financial Results

For the year ended December 31, 2008, the Company's net loss was $10,564,597, or $0.81 per basic and diluted share, compared to a net loss of $4,139,493, or $0.
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Using catalysts to stamp nanopatterns without ink
2. Experiments reveal unexpected activity of fuel cell catalysts
3. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
4. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
5. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
6. Controlling the size of nanoclusters: First step in making new catalysts
7. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
8. NIST and partners identify tiny gold clusters as top-notch catalysts
9. Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
10. Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
11. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... (PRWEB) September 12, 2014 Advancing ... and decontamination of chemical and biological threats is ... by Worcester Polytechnic Institute (WPI) and the Georgian ... the Science for Peace and Security Programme of ... of NATO’s Advanced Research Workshop series, the event ...
(Date:9/12/2014)... (PRWEB) September 12, 2014 Today, “The ... on Indiegogo. , The film, directed by former ... Aldrin, Shimon Peres, Ashton Kutcher, Will.i.Am, Michio Kaku, and ... and there’s only one university in the world devoted ... change the lives of a billion people: Singularity University. ...
(Date:9/12/2014)... 2014 Sandia Biotech, Inc. announced today ... with STC.UNM (STC) for a technology developed by researchers ... New Mexico, and Queen Mary University of London in ... Recombinant Fluorescent Antibody Technology Platform (RFAP) was developed by ... and Dr. Angray Kang from Queen Mary’s Department of ...
(Date:9/11/2014)... (hiPSCs), researchers have gained new insight into what ... of neuronal signaling associated with this disease. They ... hiPSCs of healthy individuals and of patients with ... cells to release neurotransmitters, such as dopamine, that ... to various disorders. By discovering a simple method ...
Breaking Biology Technology:Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 2Worcester Polytechnic Institute to Lead Scientific Workshop on Nanoscale Defenses for Biological and Chemical Threats 3Documentary Film that Follows Singularity University Students as They Change the World Launches its IndieGoGo Fundraising Campaign 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 2Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 3Sandia Biotech and STC.UNM Announce Option Agreement to License Novel Recombinant Antibody Technology 4Stem cells help researchers understand how schizophrenic brains function 2
... 16 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... of the company,s HIV tropism assay were presented ... Drug Resistance Workshop,in Sitges, Spain. Trofile was introduced ... in class CCR5 antagonist, in,August 2007. Recent enhancements ...
... /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.,(TSX: PLI) ... compound in clinical trial in patients with ... the European Hematology Association,held in Copenhagen, Denmark ... Director R&D, Biology, presented data on,PBI-1402 in ...
... Inc. (Nasdaq: ALXN ) today announced that ... of Alexion,Pharmaceuticals, will present at the William Blair ... a.m., local time (10:10 a.m., eastern) on,Thursday, June ... Sinha,s remarks will be available live. You can,access ...
Cached Biology Technology:Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 2Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 3Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 4Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 5Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy 6Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 2Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 3
(Date:9/12/2014)... attack from a pathogen, they sometimes respond by killing ... committing "cell suicide" to thwart further damage from the ... microscopic, spots or lesions on the plant. , But ... the plant regulates this "spotty" defense mechanism because the ... North Carolina State University have identified a number of ...
(Date:9/12/2014)... of dendritic cells in human skin have assorted functions ... report researchers in the journal EMBO Molecular Medicine ... the composition of dendritic cells in psoriatic skin lesions ... the disease. , "We urgently need new ways ... to patients and reduce the incidence of known side ...
(Date:9/11/2014)... Northumberland and Durham" by Nathaniel John Winch is re-published ... an example of combining modern information technology together with ... and data re-use. This publication will be supporting ongoing ... be seen as a model for other regions in ... the meticulous detail of old books with the interconnectedness ...
Breaking Biology News(10 mins):Corn spots: Study finds important genes in defense response 2Dendritic cells affect onset and progress of psoriasis 2Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 2Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 3
... ecosystem below an Antarctic glacier and learned that it survived ... growth. Described in the April 17 issue of ... a pool of brine trapped below Taylor Glacier and next ... Priscu , co-author of the Science article. Priscu ...
... over, Y chromosome it,s time X got some ... chromosome associated with being female, University of California, Berkeley, ... history of the X chromosome is every bit as ... important clues to the origins and benefits of sexual ...
... Sven Enerbck, Professor at the Institute of Biomedicine at the ... scientists who published their results in The New England ... Enerbck and others show that adults use brown fat to ... new possibilities in treating overweight and obesity. It has ...
Cached Biology News:Ancient ecosystem thrives millions of years below Antarctic glacier 2The story of X -- evolution of a sex chromosome 2The story of X -- evolution of a sex chromosome 3The story of X -- evolution of a sex chromosome 4
...
... Lyophilized. Lyophilized from 2 mM sodium ... human liver. Cathepsin D is a major ... as a 52 kDa proenzyme. Overexpression of ... associated with higher risk of relapse and ...
... Grade Thrombin is a highly purified preparation ... with appropriate vectors. The preparation is functionally ... is free of detectable contaminating proteases. Prepared ... by certified tests to be negative for ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
Biology Products: